BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics, today announced financial results for the full year 2020 and provided an update on its business.
“BioAtla made several achievements in 2020 that significantly enhance the company’s ability to advance our CAB clinical programs, expand our development portfolio, and further exploit the opportunities of our CAB technology,” stated Jay M. Short.
BioAtla has extensive and worldwide patent coverage for its CAB technology and products with more than 250 issued patents and more than 200 pending patent applications worldwide.
BioAtla has two CAB programs currently in Phase 2 clinical testing in the United States.
Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, expectations about the sufficiency of our cash and cash equivalents, expected R&D and G&A expenses, the timing and success of our clinical trials and related data, plans to advance development of several bispecific CAB candidates, potential for other yet to be identified PaCS molecules and potential applicability of our CAB technology in other disease related microenvironments.